About

Public Health Professor at Paris Saclay University and co-head at the INSERM “Clinical Epidemiology” research team. Specialized in therapeutic trials and cohorts in infectious diseases, her research focuses on the epidemiology and evaluation of care strategies in the fields of HIV, Covid, and pediatrics. She has been involved in the investigation of factors linked to post-treatment remissions or spontaneous remission in primary HIV infection.

Position
Researcher
Institution
Université Paris-Saclay & APHP

Linked Projects

Funded Research Project

Title: Viral dynamics of rebound and control following early treatment of HIV/SIV (NIH)

The results of the ANRS EP47 VISCONTI (Viro-Immunological Sustained COntrol after Treatment Interruption) study provided proof of concept that a state of sustainable HIV remission may be induced in at least some people with HIV: the post-treatment controllers (PTC). Unlike natural controllers, PTCs presented a symptomatic primary HIV-1 infection with high viral load and low… Continue reading Viral dynamics of rebound and control following early treatment of HIV/SIV (NIH)

Country
France
Starting year
2017
Duration
5 years
Budget
1.1M$
Members/PIs involved
Read more
Clinical Trial

Title: ANRS 175 RHIVIERA 01_Assessment of HIV remission upon ART interruption in early treated individuals from ANRS CO6 PRIMO cohort carrying the MHC genotype B35(53)Bw4TTC2

Early ART initiation seems to favor post-treatment control of infection. However, only a minority of the individuals who are treated early is able to control viremia once the treatment is interrupted. Through retrospective analyses of data available in the ANRS CO6 PRIMO cohort and the Post-treatment controllers in the ANRS VISCONTI study, we have identified… Continue reading ANRS 175 RHIVIERA 01_Assessment of HIV remission upon ART interruption in early treated individuals from ANRS CO6 PRIMO cohort carrying the MHC genotype B35(53)Bw4TTC2

Country
France
Starting year
2022
Duration
2 years
Members/PIs involved
Read more
Clinical Trial

Title: ANRS 176 RHIVIERA 02_Assessment of HIV remission upon ART interruption in individuals initiating ART in combination with two long lasting bNabs during primary infection

ART initiation during primary HIV infection limits the establishment, diversity and distribution of the viral reservoir while preserving key lymphoid organs of the deleterious effects of persistent viral replication and chronic immune activation, favoring the optimal maturation of immune responses. Early ART initiation may even facilitate long-term post-treatment control in some individuals. Therapeutic interventions during… Continue reading ANRS 176 RHIVIERA 02_Assessment of HIV remission upon ART interruption in individuals initiating ART in combination with two long lasting bNabs during primary infection

Country
France, USA
Starting year
2022
Duration
Members/PIs involved
Read more

Linked Publications

Who are the persons living with HIV who might refuse to participate in HIV cure-related clinical trials with treatment interruption?

Protiere C, Fiorentino M, Sow A, Préau M, Mora M, Fressard L, Meyer L, Lelièvre JD, Lambotte O, Spire B, Suzan-Monti M. AIDS. 2020 Jun 1;34(7):1095-1099. doi: 10.1097/QAD.0000000000002530. PMID: 32287066.

Metabolic plasticity of HIV-specific CD8 + T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection

Angin M, Volant S, Passaes C, Lecuroux C, Monceaux V, Dillies MA, Valle-Casuso JC, Pancino G, Vaslin B, Le Grand R, Weiss L, Goujard C, Meyer L, Boufassa F, Müller-Trutwin M, Lambotte O, Sáez-Cirión A. Nat Metab. 2019 Jul;1(7):704-716. doi: 10.1038/s42255-019-0081-4. Epub 2019 Jul 12. PMID: 32694646.

Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial

Chéret A, Nembot G, Mélard A, Lascoux C, Slama L, Miailhes P, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoën B, Delfraissy JF, Meyer L, Rouzioux C; OPTIPRIM ANRS Study Group. Lancet Infect Dis. 2015 Apr;15(4):387-96. doi: 10.1016/S1473-3099(15)70021-6. Epub 2015 Feb 18. PMID: 25701561.

Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study

Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C; ANRS VISCONTI Study Group. PLoS Pathog. 2013 Mar;9(3):e1003211. doi: 10.1371/journal.ppat.1003211. Epub 2013 Mar 14. PMID: 23516360; PMCID: PMC3597518.

Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers

Molinos-Albert LM, Lorin V, Monceaux V, Orr S, Essat A, Dufloo J, Schwartz O, Rouzioux C, Meyer L, Hocqueloux L, Sáez-Cirión A, Mouquet H & ANRS VISCONTI Study Group

Nature Communications Vol 13 : 1944 (2022)

Dynamics in HIV DNA levels over time in HIV Controllers.

Avettand-Fenoel V, Bayan T, Gardiennet E, Boufassa F, Lopez P, Lecuroux C, Noel N, Trémeaux P, Monceaux V, Autran B, Meyer L, Saez-Cirion A, Lambotte O, Rouzioux C; CODEX ANRS Cohort Study Group. J Int AIDS Soc. 2019 Jan;22(1):e25221. doi: 10.1002/jia2.25221. PMID: 30629340; PMCID: PMC6327944.

Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection.

Trémeaux P, Lenfant T, Boufassa F, Essat A, Mélard A, Gousset M, Delelis O, Viard JP, Bary M, Goujard C, Rouzioux C, Meyer L, Avettand-Fenoel V; ANRS-SEROCO and PRIMO cohorts. EBioMedicine. 2019 Mar;41:455-464. doi: 10.1016/j.ebiom.2019.02.016. Epub 2019 Feb 23. PMID: 30803934; PMCID: PMC6442355.